5-Amino-1MQ vs SLU-PP-332
5-Amino-1MQ (Small-molecule NNMT inhibitor) and SLU-PP-332 (Small-molecule ERR agonist (exercise mimetic)) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | 5-Amino-1MQ | SLU-PP-332 |
|---|---|---|
| Compound class | Small-molecule NNMT inhibitor | Small-molecule ERR agonist (exercise mimetic) |
| Research category | Metabolic & Mitochondrial | Metabolic & Mitochondrial |
| Length (amino acids) | Not documented | Not documented |
| Molecular weight | ~159 g/mol (free base) | ~290.3 g/mol (C18H14N2O2, CAS 303760-60-3) |
| Half-life | Not documented | Not documented |
| Origin | 5-Amino-1-methylquinolinium (5-Amino-1MQ) is a synthetic small-molecule quinolinium compound. It is not a peptide. It was identified as a cell-permeable inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). | SLU-PP-332 is a synthetic small-molecule compound reported by academic researchers (Saint Louis University) as an agonist of the estrogen-related receptors (ERRs). It is not a peptide. It has been studied as a candidate exercise-mimetic research compound. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How 5-Amino-1MQ works
5-Amino-1MQ inhibits NNMT, the enzyme that methylates nicotinamide using S-adenosylmethionine. By inhibiting NNMT, it is proposed to preserve cellular nicotinamide and NAD+ pools and reduce a metabolic sink associated with adipocyte expansion. In preclinical rodent studies, NNMT inhibition has been associated with reduced adipose tissue mass and altered cellular energy metabolism.
How SLU-PP-332 works
SLU-PP-332 is reported to act as a pan-agonist of the estrogen-related receptors (ERRalpha, ERRbeta, ERRgamma), nuclear receptors that regulate mitochondrial biogenesis, oxidative metabolism, and energy expenditure. In preclinical models, ERR activation has been associated with increased mitochondrial activity, fatty-acid oxidation, and endurance-type metabolic adaptations, prompting its description as an exercise mimetic.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
5-Amino-1MQ
SLU-PP-332
What sets each apart
5-Amino-1MQ
Distinct from the peptides in this group: it is an orally-oriented small-molecule enzyme inhibitor acting on NNMT, rather than a receptor- or fragment-based peptide.
SLU-PP-332
Unlike the peptides here, SLU-PP-332 is a nuclear-receptor-targeting small molecule; unlike AICAR (which activates AMPK), it works upstream at the ERR transcription-factor level.
Frequently asked questions
Is 5-Amino-1MQ a peptide?
No. 5-Amino-1MQ is a small-molecule NNMT inhibitor, chemically a methylquinolinium (5-amino-1-methylquinolinium) compound. It is often grouped with metabolic peptides in catalogs because of its fat-metabolism research context, but structurally it is a small molecule, not a peptide, and has no amino-acid sequence.
What is the mechanism of 5-Amino-1MQ?
5-Amino-1MQ competitively inhibits nicotinamide N-methyltransferase (NNMT) at its catalytic site. NNMT consumes S-adenosylmethionine (SAM) and methylates nicotinamide; inhibiting it is reported to raise intracellular SAM and NAD+ availability in adipocytes, shifting cells toward a more metabolically active, fat-oxidizing phenotype in preclinical models.
What is 5-Amino-1MQ studied for?
It is studied primarily in models of obesity and adipose-tissue metabolism, where NNMT is highly expressed in white/visceral fat. Preclinical rodent work reported reductions in body weight and fat mass with NNMT inhibition. Human clinical data remain limited, so findings are preclinical/mechanistic in nature.
Is the catalog name 'SLU-PP-322' correct?
The correct compound name is SLU-PP-332 (the '322' spelling is a common transposition error). SLU-PP-332 is a synthetic pan-ERR (estrogen-related receptor) agonist studied as an exercise-mimetic and metabolic compound. All information here refers to SLU-PP-332.
Is SLU-PP-332 a peptide?
No. SLU-PP-332 is a small molecule, not a peptide. Its molecular formula is C18H14N2O2 (MW ~290.3, CAS 303760-60-3), and it has no amino-acid sequence. It is grouped with metabolic peptides in catalogs because of its fat-oxidation/exercise-mimetic research context.
What is the mechanism of SLU-PP-332?
SLU-PP-332 is a pan-agonist of the estrogen-related receptors, with reported EC50 values around 98 nM (ERRalpha), 230 nM (ERRbeta), and 430 nM (ERRgamma), i.e. most potent at ERRalpha. Activating ERRalpha upregulates PGC-1alpha, driving mitochondrial biogenesis and fatty-acid oxidation, which is why it is described as an exercise mimetic.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.